Mammogram Interpretation

Chapter 2 Mammogram Interpretation


The incidence of breast cancer in women in the United States has continued to rise. The rate of increase has slowed recently, however, with the exception of in situ breast cancer, which has continued to increase. Breast cancer death rates have decreased since the early 1990s, with decreases of 2.5% per year among white women. Decreased breast cancer deaths have been attributed in part to breast cancer screening, adjuvant chemotherapy, and adoption of a healthy standard of living that includes exercise, maintenance of an appropriate body mass index, and decreased alcohol consumption. Randomized, population-controlled breast cancer screening trials using mammography have shown an approximately 30% reduction in breast cancer deaths in the women invited to screening compared to women in the control group. Because of this data, the American Cancer Society recommends annual screening mammography for women age 40 years and older.


This chapter reviews breast cancer risk factors, signs, and symptoms of breast cancer, the normal mammogram, mammographic findings of breast cancer, basic interpretation of screening mammograms, and workup of findings detected at screening with additional mammographic views.



Breast Cancer Risk Factors


Risk factors for breast cancer are important to consider when reading mammograms, because they indicate a pretest probability of breast cancer. Compiling risk information on the breast history sheet provides the interpreting radiologist quick and easy-to-use access to this information (Fig. 2-1). Breast cancer risk factors are listed in Box 2-1. The most important risk factors are older age and female gender; U.S. statistics indicate that breast cancer will develop in one in eight women, if the women have a 90-year life span. Men also develop breast cancer, but only 1% of all breast cancers occur in men.




The risk for breast cancer increases with increasing age and drops off at age 80. Women with a personal history of breast cancer have a higher risk of developing breast cancer in the ipsilateral or contralateral breast than does the general population. In women undergoing breast conservation, the conservatively treated breast has a 1% per year risk of developing cancer.


A family history of breast or ovarian cancer is a particularly important risk factor. The age, number, and cancer type in the affected relative is especially significant. Women with a first-degree relative (mother, daughter, or sister) with breast cancer have about double the risk of the general population and are at particularly high risk if that cancer was premenopausal or bilateral. If many relatives had breast or ovarian cancer, the woman may be a carrier of BRCA1 or BRCA2, the autosomal dominant breast cancer susceptibility genes. Genetic testing for these genes is possible. However, genetic testing is most appropriate when combined with the counseling, evaluation, and support provided by a genetic screening center because of the untoward social effects of positive (or negative) results. Carriers of the breast cancer susceptibility gene BRCA1 on chromosome 17 have a breast cancer risk of 85% and an ovarian cancer risk of 63% by age 70. Women with BRCA2 on chromosome 15 have a high risk of breast cancer and a low risk of ovarian cancer. These genes account for 5% of all breast cancers in the United States and for 25% of breast cancers in women younger than age 30. Women of Ashkenazi (Eastern European) Jewish heritage have a slightly higher risk of breast cancer than does the general population (Box 2-2), but additional work is being done to determine whether this population has a higher rate of breast and ovarian cancer related to BRCA1 and BRCA2 mutations. Other genetic syndromes that have a higher risk of breast cancer include the Li-Fraumeni, Cowden, and ataxia-telangiectasia syndromes.



Early menarche (before age 12), late menopause (after age 55), nulliparity, and first live birth after age 30 bestow a slightly higher risk for breast cancer, as a result of having more menstrual cycles and longer exposure to estrogen and progesterone. Data from a 2003 study, part of the Women’s Health Initiative, a randomized, controlled trial of the effects of estrogen plus progestin (combination hormone replacement therapy [CHRT]) versus placebo, showed a 24% greater incidence of breast cancer in women receiving CHRT versus the control group. Whereas previous data showed an adjusted relative risk of 1.46 for the development of breast cancer in women receiving CHRT for more than 5 years, the 2003 analysis showed the risk for breast cancer rising within 5 years of starting CHRT; in addition, it showed more difficulty in detecting cancers by mammography in this group.


A breast biopsy showing atypical ductal hyperplasia (ADH) histology increases the risk for breast cancer to four to five times that of the general population. The presence of lobular carcinoma in situ (LCIS) also increases the risk for breast cancer, but at a much higher rate than ADH, about 10 times that of the normal population. LCIS is a misnomer and not a cancer at all. Rather, LCIS is a high-risk marker for developing breast cancer. A woman with LCIS has a 27% to 30% chance of developing invasive ductal or lobular cancer in the ipsilateral or contralateral breast over a 10-year period. Thus, a biopsy showing LCIS results in patient management of either “watchful waiting” with increased surveillance by frequent imaging and physical examination, or bilateral mastectomy.


Women who had an early exposure to radiation also have an increased risk for breast cancer. A medical history of radiation therapy for Hodgkin disease, multiple fluoroscopic examinations for tuberculosis, ablation of the thymus, or treatment of acne with radiation infers possible scattered radiation to the breasts, which may induce breast cancer. In fact, the risk for developing breast cancer is so high in women with Hodgkin disease that in 2008 the American Cancer Society recommended magnetic resonance screening for Hodgkin’s disease survivors.


Extensive mammographic breast density, or a large amount of fibroglandular tissue within the breast by volume as measured on the mammogram, is strongly associated with the risk of breast cancer. However, the association and the reasons for this finding, as well as its relative association among different ethnicities, are still being studied.


Other lifestyle choices also affect breast cancer risk. One is drinking alcohol. One drink per day bestows a very small risk, but two to five drinks per day increases the risk to 15 times that of women who do not drink. Being overweight or obese also increases the risk of cancer, especially if the weight gain happens after menopause and the fat is around the abdomen. A woman with an “apple-shaped” body is at higher risk than one with a “pear-shaped” body. Exercise has been shown to reduce breast cancer risk after menopause, with one study suggesting that cancer risk was reduced at least in part via hormonal pathways. However, more study of these changeable risk factors is needed.


Quantitative statistical models that estimate the short-term or lifetime risk for breast cancer include the Claus model and the Gail statistical model. These models compile individual risk factors and combine them into an estimate of the lifetime risk for breast cancer for individual women.


Despite all these risk factors, it remains true that 70% of all women with breast cancer have none of these risk factors other than older age and female gender.



Signs and Symptoms of Breast Cancer


Women, or their partners, often find their own breast cancer by discovering a palpable hard breast lump. Breast lumps are a common symptom for which women seek advice (Box 2-3). Of particular concern are new, growing, or hard breast masses. Masses that are stuck to the skin or chest wall are particularly worrisome for an invasive breast cancer.



Nipple discharge is another finding for which women often seek advice. Nipple discharge is usually benign, especially if it is whitish, green, or yellow and is produced from several ducts. Nipple discharge is suspicious for cancer if it is new, expressed from only one duct, bloody or serosanguineous, spontaneous, copious, or serous. An example of a suspicious history is a woman finding new bloody or serous nipple discharge on her nightgown or undergarments.


Nipple inversion is a sign of breast cancer if it is new. Longstanding nipple inversion is not uncommon, however; inverted nipples may be present at birth and are benign. On the other hand, new nipple inversion is of concern because a retroareolar tumor can produce nipple retraction.


Similarly, skin retraction or dimpling is a sign of breast cancer, due to tethering of the skin by cancer. On physical examination, skin retraction or tethering may be seen with the patient’s arms at her sides when she inspects her breasts in the mirror. Raising the patient’s arms or placing her hands on her hips pulls in the pectoralis muscle and may show skin tethering under the breasts that was previously invisible or may make the tethering more apparent.


Peau d’orange is a physical finding indicating breast edema; it is caused by skin edema rising around the bases of tethered hair follicles, resulting in skin pitting, or “orange peel” skin. Breast edema is a nonspecific finding and may indicate inflammatory cancer, mastitis, or axillary lymph node obstruction.


Despite all these signs and symptoms of breast cancer, some women have no physical findings or symptoms at all despite having breast cancer. Their breast cancers are detected on screening mammography.


Breast pain is not generally caused by cancer, but it deserves mention because it is a common cause of morbidity. If cyclic, breast pain is usually endocrine in nature. Although breast pain is usually due to benign etiologies, unfortunately, both breast pain and breast cancer are common. Thus, the physician’s goals are to reassure patients with breast pain, search for treatable causes of breast pain such as cysts, and exclude coexistent malignancy.



The Normal Mammogram


A normal breast is composed of a honeycomb supporting fibrous structure made up of Cooper ligaments that houses fatty tissue, which in turn supports the glandular elements of the breast (Fig. 2-2A). The glandular elements are composed of lactiferous ducts leading from the nipple and branching into excretory ducts, interlobular ducts, and terminal ducts leading to the acini that produce milk. The ducts are lined throughout their course by epithelium composed of an outer myoepithelial layer of cells and an inner secretory cell layer. The ducts and glandular tissue extend posteriorly in a fanlike distribution consisting of 15 to 20 lobes draining each of the lactiferous ducts, with most of the dense tissue found in the upper outer quadrant. Posterior to the glandular tissue is retroglandular fat, described by Dr. Laszlo Tabar as a “no man’s land,” in which no glandular tissue should be seen. The pectoralis muscle lies behind the fat on top of the chest wall.



On the normal mediolateral oblique (MLO) mammogram, the pectoralis muscle is a concave structure posterior to the retroglandular fat near the chest wall. Normal lymph nodes high in the axilla overlie the pectoralis muscle (see Fig. 2-2B and C). Normal lymph nodes are sharply marginated, oval, or lobulated dense masses with a radiolucent fatty hilum. They are commonly found in the upper outer quadrant of the breast along blood vessels. Lymph nodes also occur normally within the breast and are known as normal “intramammary” lymph nodes. If the lymph node has the typical kidney bean shape and a fatty hilum, it should be left alone. If one is uncertain about whether a mass represents an intramammary lymph node, mammographic magnification views may help display the fatty hilum, or ultrasound may show the typical hypoechoic appearance of the lymph node and the echogenic fatty hilum.


Usually fibroglandular tissue occurs symmetrically in the upper outer quadrants of the breasts. The breast tissue is usually distributed fairly symmetrically from left to right. When viewing mammograms, the clinician should place the mammograms back to back so that the chest walls face each other for easy viewing of tissue symmetry (see Fig. 2-5A). Fatty tissue surrounds the glandular tissue.


On the normal craniocaudal (CC) projection, the pectoralis muscle produces a half-moon–shaped density near the chest wall (Fig. 2-3A and B). Fat lies anterior to the muscle, and the white glandular tissue lies anterior to the fat. In older women, most of the glandular tissue in the medial breast undergoes fatty involution, and therefore most of the residual dense glandular tissue exists in the upper outer breast.



There should be only fatty tissue in the medial breast near the chest wall. The only normal exception is the sternalis muscle, a muscular density near the medial aspect of the chest wall that should not be mistaken for a mass (see Fig. 2-3C and D). If there is a question that the density is a mass instead of the sternalis muscle, a cleavage view (CV) mammogram or ultrasound can prove that the density is a muscle and a normal structure.


Breast “density” is an important feature of the mammogram that describes how much of the breast is filled with glandular tissue, which looks white on the mammogram. Fat is black on the mammogram. Women normally have varying ratios of glandular and fatty tissue in their breasts. A “dense” mammogram has very glandular breast tissue in it and looks mostly white. The opposite of a “dense” mammogram is a “fatty” mammogram, which looks mostly black. Because breast cancer is also white on the mammogram, a white “dense” normal background of glandular tissue can hide a cancer, just like a polar bear can hide in a snowstorm.


The American College of Radiology’s (ACR) Breast Imaging Reporting and Data System (BI-RADS®) lexicon separates breast density into quartiles depending on how much glandular tissue the breast contains by volume. “Dense” contains the most white (>75% dense), “heterogeneously dense” is less white (50–75% dense), “scattered fibroglandular” is even less white (25–50%), and “fatty” is the least white (<25% dense) (Box 2-4). A “dense” breast does not mean the breast is hard to the touch. Breast density has little correlation to how hard or soft the breast feels on physical examination; that is, you cannot predict how soft a breast will feel by looking at the mammogram. Radiologists describe breast density in the mammogram report so that referring doctors will know how white the breast looks and how confident the radiologist is in excluding cancer.



Young women have mostly glandular breasts, and their mammograms are described as “dense.” As women age, the fibroglandular tissue involutes into fat, which is black. The natural progression of the mammogram is mostly white (dense) at a young age when the breasts are filled with glandular tissue, becoming progressively darker as the woman ages and her glandular tissue turns into fat. The amount of remaining glandular tissue varies from woman to woman. Some older women have surprisingly large amounts of dense white tissue on the mammogram; the amount remaining depends on genetics, parity, and exogenous hormone replacement therapy. But generally as women age, the glandular tissue involutes so that there are relatively greater amounts of dense glandular tissue remaining in the upper outer quadrant of the breast and darker fatty areas in the medial and lower part of the breast. In some women, only fatty tissue is left after the menopause (Fig. 2-4).



It is important to know about the relative decrease in breast tissue and breast density over time. Increases in breast density in normal women occur only in pregnant and lactating women, or in women starting exogenous hormone replacement therapy. Unexplained generalized increases in breast density may indicate breast edema or inflammatory cancer. New focal density should prompt investigation because a developing density may represent a cancer.


Breast tissue is usually symmetric, or “mirror image,” when comparing left to right mammograms, although 3% of women have normal asymmetric glandular tissue. Normal asymmetric glandular tissue is a larger volume of normal fibroglandular tissue in one breast than in the other, but with one breast not necessarily being larger than the other. One method of evaluating for symmetry is to view the left and right MLO mammograms back to back and the CC mammograms back to back. The glandular tissue pattern is usually fairly symmetric from side to side, and asymmetries are easily identified using this technique (Fig. 2-5A to C).



A normal mammogram does not usually change from year to year after taking into account the normal involution of glandular tissue over time. Because the mammogram stays the same from year to year, comparing old studies with current studies makes it easier to see new or developing changes. For this reason, older films of good quality are placed next to the new films to look for subtle change (see Fig 2-5D to H). Because subtle changes may take longer than a year to become evident, one should compare both last year’s films and films more than 2 years old (or the oldest films of comparable quality) to the new ones. If the mammograms are screen-film studies, the images are viewed on a high-intensity view box with the light parts of the films masked to block extraneous light. For full-field digital mammograms (FFDMs) viewed on soft copy, the images are displayed on high-resolution bright monitors in a dark room with little to no ambient light, comparing old mammograms to new ones in the display protocol.



Mammographic Findings of Breast Cancer


Mammographic detection of breast cancer depends on the sensitivity of the test, the experience of the radiologist, the morphologic appearance of the tumor, and the background on which it is displayed. Cause for a “missed” breast cancer can usually be traced to one of these factors (Table 2-1).


Table 2-1 Reasons for Missed Cancers


















Errors in technique
Errors in detection
Errors in interpretation Radiologist sees and perceives finding, incorrectly interprets finding as nonactionable
Tumor morphology Tumor shape similar to background fibroglandular tissue displayed on the mammogram
True negative study Tumor cannot be seen even in retrospect

Radiologists see breast cancers on screening mammography because they see pleomorphic calcifications or spiculations produced by the tumor. Radiologists also may see architectural distortion, asymmetric density, a developing density, a round mass, breast edema, lymphadenopathy, or a single dilated duct, which are the other mammographic signs of breast cancer. The radiologist has to not only see the finding, but to also recognize that the finding is abnormal and correctly interpret the study as needing further action (i.e., is “actionable”) (Box 2-5).



The mammographic signs of breast cancer listed in Table 2-2 are discussed in further detail in Chapter 3 on breast calcifications, Chapter 4 on breast masses, and Chapter 10 on clinical problems. The trick is to see the cancer, perceive it and have it register in one’s mind, then interpret the findings correctly and act on the finding.


Table 2-2 Mammographic Findings of Breast Cancer







































Finding Differential Diagnosis
Pleomorphic calcifications Cancer (most common), benign disease, fat necrosis
Spiculated mass Cancer, postsurgical scar, radial scar, fat necrosis
Round mass Cyst, fibroadenoma, cancer, papilloma, metastasis
Architectural distortion Postsurgical scarring, cancer
Developing density Cancer, hormone effect, focal fibrosis
Asymmetry: focal or global Normal asymmetric tissue (3%), cancer (suspicious: new, palpable, a mass containing suspicious calcifications or spiculation)
Breast edema
Lymphadenopathy
Single dilated duct Normal variant, papilloma, cancer
Mass with calcifications Cancer, fibroadenoma, papilloma; exclude calcifying oil cyst
Nothing 10% of all cancers are false-negative on mammography

Between 10% and 15% of breast cancers are mammographically occult, which means that breast cancer is present but the mammogram is normal. Accordingly, if there are suspicious clinical symptoms or physical findings and the mammogram is negative, the decision for biopsy should be based on clinical grounds alone.


The ability of mammography to depict breast cancer is optimized by good mammographic technique and positioning, which produces the best chance to display suspicious findings against the normal breast background. Mammographic signs of breast cancer are not seen as well against a dense or fibroglandular background, which hides masses and tiny pleomorphic calcifications. Suspicious masses also may be lost in a “busy” background of round benign cysts or extensive benign calcifications that draw the radiologist’s attention away from the cancer. Therefore, the radiologist needs a systematic approach to the mammogram to ensure a consistent, reproducible search pattern. Later, a re-review of “danger zones” where cancers are commonly missed will help the radiologist avoid mistakes.



An Approach to the Mammogram


Many tools are available to help the radiologist correctly interpret mammograms (Table 2-3). The first is the breast history and physical findings. The breast history sheet alerts the radiologist to the patient’s risk factors for cancer and the patient’s pretest probability of cancer (see Fig. 2-1). The history sheet includes the patient’s clinical history of breast biopsies and a schematic diagram of their location so that old scars are not misinterpreted as cancer.


Table 2-3 Tools Used for Interpretation of Mammograms






























Tool Use
Breast history, risk factors Evaluate patient’s complaint and risks
Technologist’s marks Show skin lesions, scars, problem areas
Putting images back to back
Bright light (SFM) View skin, dark parts of film
Window/level (FFDM) Contrast for masses, calcifications
Magnifying lens or magnifier Visualize mass borders, calcifications
Old films Compare for changes
CAD (if available) Look for CAD marks after initial interpretation

CAD, computer-aided detection; FFDM, full-field digital mammogram; SFM, screen-film mammogram.


A technologist or aide usually interviews the patient, marking the location of any palpable finding on a diagram on the history sheet. Positions of findings in the breast are described in breast quadrants, with the upper outer quadrant representing the breast quadrant nearest the axilla. Another way to describe a breast location is by using the “clock face” method, in which the location of breast findings is described as though a clock were superimposed on each breast as the woman faces the examiner (Fig. 2-6). This means that the upper outer quadrant in the right breast is between the 9- and 12-o’clock positions, but the upper outer quadrant in the left breast is between the 12- and 3-o’clock positions.


Stay updated, free articles. Join our Telegram channel

Dec 24, 2015 | Posted by in BREAST IMAGING | Comments Off on Mammogram Interpretation

Full access? Get Clinical Tree

Get Clinical Tree app for offline access